Is brigatinib effective for targeted treatment of non-small cell lung cancer?

In the targeted treatment of non-small cell lung cancer, brigatinib is an important drug, and its usability is reflected in many aspects.

Brigatinib has achieved remarkable results in the treatment ofALK mutation-positive non-small cell lung cancer. This lung cancer characteristic is closely related to the malignancy and prognosis of the tumor. By inhibiting the expression of ALK protein, brigatinib can effectively inhibit tumor growth, thereby improving patients' quality of life and prolonging survival. Clinical trials have shown that patients treated with brigatinib have obvious advantages in tumor shrinkage and delayed disease progression.

The targeting specificity of brigatinib is another major advantage. It can selectively inhibit kinases in tumor cells and reduce damage to normal cells. This property allows patients to better tolerate treatment and reduces the risk of adverse effects. Compared with traditional chemotherapy, brigatinib's targeted therapy is more precise and reduces unnecessary side effects.

The way brigatinib is administered also brings convenience to patients. It is administered orally, allowing patients to self-administer it at home, avoiding frequent hospital visits. This method of medication not only simplifies the treatment process, but also improves the patient's quality of life.

The dosage of brigatinib can be adjusted according to the patient's specific condition. The doctor will determine the appropriate dose and treatment plan based on the patient's condition, physiological condition, and tolerance. This personalized treatment helps maximize the therapeutic effect of the drug while minimizing the impact of side effects on the patient.

Brigatinib also has certain side effects, such as nausea, vomiting, diarrhea, abnormal liver function, etc. Therefore, patient response needs to be closely monitored while using brigatinib and adjustments made accordingly as needed.

References:

https://pubmed.ncbi.nlm.nih.gov/32986959/